NovaBay Pharmaceuticals, Inc Provides Earnings Guidance for the Fourth Quarter and Full Year of 2017
January 08, 2018 at 05:20 pm IST
Share
NovaBay Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full year of 2017. For the quarter, the company expected total sales expected to slightly exceed $6 million, up 49% over fourth quarter of 2016. Gross margin on Avenova product sales expected in the low 90% range.
For the full year, the company expected total revenue for the full year of 2017 is expected to be approximately $18 million, up 51% from 2017.
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
NOVABAY PHARMACEUTICALS, INC. 
